FDA approves genetic test for breast cancer treatment

06/15/2011 | Wall Street Journal, The

Ventana Medical Systems, a Roche Holding subsidiary, has received FDA approval for its Inform Dual ISH genetic test, which is designed to identify patients who are likely to benefit from Herceptin, Genentech's breast cancer drug. The test works by looking for the presence of the HER2 gene in patients' tumor samples.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC